Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1980 Aug;18(2):269–275. doi: 10.1128/aac.18.2.269

Antiviral activity of antilipidemic compounds on herpes simplex virus type 1.

J K Mehl, D T Witiak, V V Hamparian, J H Hughes
PMCID: PMC283982  PMID: 6255860

Abstract

Two antilipidemic compounds, clofibrate and procetofene, inhibited the replication of herpes simplex virus type 1 (HSV-1) in African green monkey kidney cells. Clofibrate, at a concentration of 400 mumol/liter caused a 63% reduction (P < 0.001) in HSV-1 yield and at 100 mumol/liter caused a 62% reduction (P < 0.001) in plaque formation. Two stereoisomeric analogs of clofibric acid, (-)- and (+)-desmethyl clofibric acid, also caused a significant inhibition of HSV-1 replication. Procetofene at 5 mumol/liter caused a 56% reduction (P < 0.001) in HSV-1 plaques and at 10 mumol/liter caused a significant reduction (P < 0.001) in both viral yield (42 to 54%) and plaque formation (65%). Procetofene also inhibited the development of HSV-1 plaques. A concentration of 5 mumol/liter resulted in a 26% reduction (P < 0.001) in plaque diameter. Because of their nonspecific inhibitory effect on the uptake of cellular macromolecular precursors for nucleic acid and protein biosynthesis, these antilipidemic compounds may exert their antiviral activity by affecting one or more key metabolic host cell pathways.

Full text

PDF
274

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brodie R. R., Chasseaud L. F., Elson F. F., Franklin E. R., Taylor T. Antilipidemic drugs. Part 4: The metabolic fate of the hypolipidemic agent isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-protionate (LF 178) in rats, dog and man. Arzneimittelforschung. 1976;26(5):896–901. [PubMed] [Google Scholar]
  2. Cederbaum A. I., Rubin E. Effects of clofibrate on mitochondrial function. Biochem Pharmacol. 1974 Jul 15;23(14):1985–1996. doi: 10.1016/0006-2952(74)90257-3. [DOI] [PubMed] [Google Scholar]
  3. Fallon H. J., Adams L. L., Lamb R. G. A review of studies on the mode of action of clofibrate and betabenzalbutyrate. Lipids. 1972 Feb;7(2):106–109. doi: 10.1007/BF02532596. [DOI] [PubMed] [Google Scholar]
  4. Ferguson T. F., Prottey C. A simple and rapid method for assaying cytotoxicity. Food Cosmet Toxicol. 1974 Jun;12(3):359–366. doi: 10.1016/0015-6264(74)90008-x. [DOI] [PubMed] [Google Scholar]
  5. Gentry G. A., Aswell J. F. Inhibition of herpes simplex virus replication by araT. Virology. 1975 May;65(1):294–296. doi: 10.1016/0042-6822(75)90034-3. [DOI] [PubMed] [Google Scholar]
  6. Grossberg S. E., Roch L. A., Frerman F. E. The inhibition of lipid-containing viruses by an antilipemic agent. Prog Immunobiol Stand. 1971;5:289–293. [PubMed] [Google Scholar]
  7. Gugler R., Hartlapp J. Clofibrate kinetics after single and multiple doses. Clin Pharmacol Ther. 1978 Oct;24(4):432–438. doi: 10.1002/cpt1978244432. [DOI] [PubMed] [Google Scholar]
  8. Gurrieri J., Lous M. L., Renson F. J., Tourne C., Voegelin H., Majoie B., Wüfert E. Antilipidemic drugs. Part 2: Experimental study of a new potent hypolipidemic drug, isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-propionate (LF178). Arzneimittelforschung. 1976;26(5):889–894. [PubMed] [Google Scholar]
  9. Kaneko I., Hazama-Shimada Y., Kuroda M., Endo A. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cultured L cells by the hypocholesterolemic drug clofibrate. Biochem Biophys Res Commun. 1977 Jun 20;76(4):1207–1213. doi: 10.1016/0006-291x(77)90984-6. [DOI] [PubMed] [Google Scholar]
  10. Katyal S. L., Saha J., Kabara J. J. Effect in vitro of clofibrate and trans-1,4-bis-(2-chlorobenzylaminoethyl)-cyclohexane dihydrochloride (AY 9944 ) on respiration and adenosine triphosphatase activity of mouse liver mitochondria. Biochem Pharmacol. 1972 Mar 1;21(5):747–751. doi: 10.1016/0006-2952(72)90070-6. [DOI] [PubMed] [Google Scholar]
  11. Mackerer C. R., Haettinger J. R. Further studies concerning the effects of clofibrate on respiration and oxidative phosphorylation of rat liver mitochondria. Biochem Pharmacol. 1974 Dec 1;23(23):3331–3345. doi: 10.1016/0006-2952(74)90658-3. [DOI] [PubMed] [Google Scholar]
  12. Mackerer C. R., Haettinger J. R., Hutsell T. C. Effects of clofibrate, in vitro, on mitochondrial respiration and oxidative phosphorylation. Biochem Pharmacol. 1973 Feb 15;22(4):513–519. doi: 10.1016/0006-2952(73)90294-3. [DOI] [PubMed] [Google Scholar]
  13. Maragoudakis M. E., Hankin H. On the mode of action of lipid-lowering agents. V. Kinetics of the inhibition in vitro of rat acetyl coenzyme A carboxylase. J Biol Chem. 1971 Jan 25;246(2):348–358. [PubMed] [Google Scholar]
  14. Maragoudakis M. E., Hankin H., Wasvary J. M. On the mode of action of lipid-lowering agents. VII. In vivo inhibition and reversible binding of hepatic acetyl coenzyme A carboxylase by hypolipidemic drugs. J Biol Chem. 1972 Jan 25;247(2):342–347. [PubMed] [Google Scholar]
  15. Pan H. Y., Chou S. C. The effects of clofibrate on cell division of log phase and synchronized cells and on macromolecular synthesis in Tetrahymena pyriformis, GL. Comp Biochem Physiol C. 1978;60(2):221–223. doi: 10.1016/0306-4492(78)90098-9. [DOI] [PubMed] [Google Scholar]
  16. Rouffy J., Dreux C., Goussault Y., Dakkak R., Renson F. J. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV). Arzneimittelforschung. 1976;26(5):901–906. [PubMed] [Google Scholar]
  17. Thomas J., Debeer L. J., Mannaerts G. P. Increased hepatic fatty-acid oxidation in clofibrate-treated rats [proceedings]. Arch Int Physiol Biochim. 1978 May;86(2):459–461. [PubMed] [Google Scholar]
  18. Walsh M. R., Teal S. W., Gamble W. Biosynthesis of cholesterol by the bovine aorta and the mechanism of action of alpha-para-chlorophenoxyisobutyric acid. Arch Biochem Biophys. 1969 Mar;130(1):7–18. doi: 10.1016/0003-9861(69)90003-4. [DOI] [PubMed] [Google Scholar]
  19. Witiak D. T., Hackney R. E., Whitehouse M. W. Inhibition of cholesterolgenesis in vitro by chlorophenoxyacetic acids. Effect of alpha-methyl groups. J Med Chem. 1969 Jul;12(4):697–699. doi: 10.1021/jm00304a034. [DOI] [PubMed] [Google Scholar]
  20. Witiak D. T., Ho T. C., Hackney R. E., Connor W. E. Hypocholesterolemic agents. Compounds related to ethyl alpha-(4-chlorophenoxy)-alpha-methylpropionate. J Med Chem. 1968 Sep;11(5):1086–1089. doi: 10.1021/jm00311a048. [DOI] [PubMed] [Google Scholar]
  21. Wülfert B., Majoie B., de Ceaurriz A. Antilipidemic drugs. Part 6: LF 178 in man. A preliminary note on a multicenter investigation bearing on 393 subjects with pure or mixed forms of hyperlipidemia. Arzneimittelforschung. 1976;26(5):906–909. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES